A Phase IV, Randomized, Double-Blind, Placebo-Controlled Exploratory Study of Xolair (Omalizumab) for Treatment of Idiopathic Angioedema in Patients Who Remain Symptomatic Despite Current Therapy
Latest Information Update: 02 Nov 2022
At a glance
- Drugs Omalizumab (Primary)
- Indications Angioedema
- Focus Therapeutic Use
- 12 Jun 2020 Status changed from active, no longer recruiting to completed.
- 22 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 13 Nov 2019 Planned End Date changed from 31 Dec 2019 to 30 Mar 2020.